Akston Biosciences Advances Longer-Lasting Treatments for Pets
Chronic conditions can make life harder for pets and their owners. Many conditions require ongoing care and repeated treatments. Longer-lasting therapies could help reduce the number of treatments pets need.
Akston Biosciences, a Propel(x) portfolio company, is working toward this goal. The company develops protein-based therapies for companion animals through its Ambifect® platform.
The platform uses a targeted approach to engage the immune system. Akston is developing the technology to create longer-lasting therapeutic responses against specific disease targets.
Developing New Treatments for Companion Animals
Veterinary care continues to advance as researchers explore new ways to treat chronic conditions. At the same time, pet owners and veterinarians often look for treatments that can reduce the burden of frequent dosing.
Akston focuses on this area through its animal-health pipeline.
The company’s programs target conditions that affect companion animals, including atopic dermatitis and osteoarthritis. Recent company-reported data highlight progress across both areas.
AKS-699 Shows Sustained Reduction in Itching
One of Akston’s leading programs is AKS-699. The company is developing this Ambifect® anti-IL-31 candidate for conditions linked to itching in dogs.
In a canine challenge study, AKS-699 maintained a greater than 80% reduction in pruritus through one year, according to company-reported data.
The study also compared pruritus control with lokivetmab. Akston reported comparable control while the study required fewer treatments.
These findings could be important for chronic skin conditions. Persistent itching can affect a pet’s comfort and daily life. Therefore, treatments that maintain their effect for longer periods could help reduce treatment frequency.
Advancing Osteoarthritis Treatments
Akston is also developing treatments for osteoarthritis pain in dogs.
The company presented head-to-head data for its NGF-targeting candidates, AKS-548d and AKS-734, at the 2026 ACVIM Forum.
According to Akston, both candidates showed clinically meaningful reductions in osteoarthritis pain. The candidates also showed improvements in function.
The reported results were generally consistent with those observed with bedinvetmab (Librela®).
Akston also reported results from a supplemental cohort for AKS-548d. The candidate showed detectable anti-NGF antibody responses through approximately Day 120.
These results support further investigation into longer dosing intervals.
Expanding Biologics Manufacturing
Akston’s recent progress extends beyond its research programs.
The company opened a new biologics manufacturing facility in Caddo Parish, Louisiana. The facility has support from a reported $7 million investment and is expected to create 69 direct jobs.
Manufacturing capacity can become increasingly important as a biotechnology company moves its programs forward.
The new facility gives Akston additional infrastructure for biologics manufacturing. It also supports the company’s broader efforts to build a scalable animal-health business.
Akston Files for an Initial Public Offering
Akston has also taken steps toward becoming a publicly traded company.
The company filed for an initial public offering on NYSE American under the ticker AXTN.
This filing marks another development as Akston continues to advance its pipeline and manufacturing operations.
A Focus on Treatment Durability
Across its pipeline, Akston is exploring ways to make veterinary treatments last longer.
This focus could have practical benefits for pets, veterinarians, and pet parents. Fewer treatments may reduce the need for repeated visits and dosing.
At the same time, continued research will determine how these candidates perform as development progresses.
Akston’s work combines protein therapeutics with targeted approaches to companion-animal health. Its programs cover areas such as skin disease and osteoarthritis.
Advancing Companion-Animal Health
Akston Biosciences continues to advance its therapeutic pipeline while expanding its manufacturing capabilities.
The company’s recent progress includes new data for AKS-699, AKS-548d, and AKS-734. It also includes the opening of a new Louisiana manufacturing facility and the filing for an initial public offering.
Together, these developments show the different areas Akston is building across its business.
We’re proud to see the Akston Biosciences team continue developing potential treatment options for companion animals while working toward longer-lasting therapies and scalable manufacturing.
Learn more about Akston Biosciences on Propelx.com.
